Diagnostic and prognostic biomarkers of sepsis in critical care

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 2, 2011, Pages

  Kibe, Savitri ^a   Adams, Kate ^a   Barlow, Gavin ^a,b  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antibiotic stewardship; Intensive care; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN;

ACCURACY; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DELAYED DIAGNOSIS; DRUG EXPOSURE; HUMAN; INTENSIVE CARE; MORTALITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CRITICAL CARE; CRITICAL ILLNESS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; GREAT BRITAIN; HUMANS; PROGNOSIS; PROTEIN PRECURSORS; SEPSIS;

EID: 79952611907     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq523     Document Type: Article

References (52)

1. Kumar A, Roberts D, Wood K et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
2. Harbarth S, Holeckova K, Froidevaux C et al. Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients with suspected sepsis. Am J Resp Crit Care Med 2001; 164: 396-402.
3. Ho KM, Towler SC. A comparison of eosinopenia and C-reactive protein as a marker of bloodstream infections in critically ill patients: a case-control study. Anaesth Intensive Care 2009; 37: 450-6.
4. Guignant C, Voirin N, Venet F et al. Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 2009; 35: 1859-67.
5. Seligman R, Papassotiriou J, Morgenthaler NG et al. Prognostic value of midregional pro-atrial natriuretic peptide in ventilator-associated pneumonia. Intensive Care Med 2008; 34: 2084-91.
6. Wu HP, Chen CK, Chung K et al. Plasma transforming growth factor-b1 level in patients with severe community-acquired pneumonia and association with disease severity. J Formos Med Assoc 2009; 108: 20-7.
7. Koch A, Gressner OA, Sanson E et al. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009; 13: R95.
8. O'Grady NP, Barie PS, Bartlett JG et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008; 36: 1330-49.
9. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiologica 2009; 75: 447-52.
10. Shehabi Y, Seppelt I. Pro/con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care 2008; 12: 211-6.
11. Charles PE, Ladoire S, Aho S et al. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram-negative or Gram-positive bacteria. BMC Infect Dis 2008; 8: 38.
12. Perren A, Cerutti B, Lepori M et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008; 36: 163-6.
13. Preas HL, Nylen ES, Snider RH et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxaemia. J Infect Dis 2001; 184: 373-6.
14. Reinhart K, Karzai W, Meisner M. Procalcitonin as a systemic inflammatory response to infection. Intensive Care Med 2000; 26: 1193-200.
15. Opatrná S, Klaboch J, Opatrný K Jr et al. Procalcitonin levels in peritoneal dialysis patients. Perit Dial Int 2005; 25: 470-2.
16. Lindberg M, Hole A, Johnsen H et al. Reference intervals for procalcitonin and C-reactive protein after major abdominal surgery. Scand J Clin Lab Invest 2002; 62: 189-94.
17. Uzzan B, Cohen R, Nicholas P et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34: 1996-2003.
18. Tang BMP, Eslick GD, Craig JC et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 210-7.
19. Ruiz-Alvarez MJ, García-Valdecasas S, De Pablo R et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 2009; 24: 63-71.
20. Rau BM, Kemppainen EA, Gumbs AA et al. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg 2007; 245: 745-54.
21. Bouadma L, Luyt C-E, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463-74.
22. Charles PE, Kus E, Aho S et al. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009; 9: 49-58.
23. Luyt CE, Combes A, Reynaud C et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008; 34: 1434-40.
24. Tsangaris I, Plachouras D, Kavatha D et al. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009; 9: 213-21.
25. Jensen J-U, Lundgren B, Hein L et al. The Procalcitonin and Survival Study (PASS) - a randomised multi-centre investigator initiated trial to investigate whether daily measurements biomarker procalcitonin and pro-active diagnostic and therapeutic responses to abnormal procalcitonin levels can improve survival in intensive care unit patients. BMC Infect Dis 2008; 8: 91-101.
26. Giamarellos-Bourboulis EJ, Mega A, Grecka P et al. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002; 28: 1351-6.
27. Jensen JU, Heslet L, Jensen TH et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-602.
28. Pettila V, Hynninen M, Takkunen O et al. Predictive value of procalcitonin and interleukin-6 in critically ill patients with suspected sepsis. Intensive Care Med 2002; 28: 1220-5.
29. Schneider CP, Yilmaz Y, Kleespies A et al. Accuracy of procalcitonin for outcome prediction in unselected postoperative critically ill patients. Shock 2009; 31: 568-73.
30. Fritz HG, Brandes H, Bredle DL et al. Post-operative hypoalbuminaemia and procalcitonin elevation for prediction of outcome in cardiopulmonary bypass surgery. Acta Anaesthesiol Scand 2003; 47: 1276-83.
31. Rau BM, Frigerio I, Büchler MW et al. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg 2007; 142: 134-42.
32. Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitoninbased guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-66.
33. Burkhardt O, Ewig S, Haagen U et al. A simple procalcitonin-guided strategy results in safe reductions of antibiotic use in patients with symptoms of acute respiratory tract infections in primary care. Eur Resp J 2010; 36: 601-7.
34. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
35. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Resp Crit Care Med 2006; 174: 84-93.
36. Nobre V, Harbarth S, Graf J-D et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomised trial. Am J Respir Crit Care Med 2008; 177: 498-505.
37. Hochreiter M, Kohler T, Schweiger AM et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomised prospective controlled trial. Crit Care 2009; 13: R83.
38. Stolz D, Smyrnios N, Eggimann P et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Resp J 2009; 34: 1364-75.
39. Venkatesh B, Kennedy P, Kruger PS et al. Changes in serum procalcitonin and C-reactive protein following antimicrobial therapy as a guide to antibiotic duration in the critically ill: a prospective evaluation. Anaes Intensive Care 2009; 37: 20-6.
40. Chastre J, Wolff M, Fagon J-Y et al. PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator associated pneumonia in adults. A randomised trial. JAMA 2003; 290: 2588-98.
41. Abidi K, Khoudri I, Belayachi J et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care 2008; 12: R59.
42. Shaaban H, Daniel S, Sison R et al. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care 2010; 25: 570-5.
43. Rintala EM, Aittoniemi J, Laine S et al. Early identification of bacteremia by biochemical markers of systemic inflammation. Scand J Clin Lab Invest 2001; 61: 523-30.
44. Kinasewitz GT, Yan SB, Basson B et al. PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8: R82-90.
45. Dempfle CE, Lorenz S, Smolinski M et al. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004; 32: 520-4.
46. Chopin N, Floccard B, Sobas F et al. Activated partial thromboplastin time waveform analysis: a new tool to detect infection? Crit Care Med 2006; 34: 1654-60.
47. Zakariah AN, Cozzi SM, Van Nuffelen M et al. Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients. Crit Care Med 2008; 36: 1507-12.
48. Schuetz P, Christ-Crain M, Morgenthaler NG et al. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007; 14: 345-51.
49. Wang RL, Kang FX. Prediction about severity and outcome of sepsis by pro-atrial natriuretic peptide and pro-adrenomedullin. Chin J Traumatol 2010; 13: 152-7.
50. Ueda S, Nishio K, Akai Y et al. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 2006; 26: 134-9.
51. Hoffmann U, Bertsch T, Dvortsak E et al. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis. Scand J Infect Dis 2006; 38: 867-72.
52. Sundén-Cullberg J, Nyström T, Lee ML et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 2007; 35: 1536-42.